Format

Send to

Choose Destination
Haematologica. 2019 Jan 31. pii: haematol.2018.212001. doi: 10.3324/haematol.2018.212001. [Epub ahead of print]

Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A.

Author information

1
CHU de Caen, Haematology laboratory, Caen, France.
2
Hopital Cochin Paris, France.
3
Department of Pathophysiology and Transplantation, Università degli Studi di Milano.
4
INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris.
5
Centres de traitement de hémophilie, APHP, Le Kremlin-Bicêtre, France.
6
Centres de traitement de hémophilie, APHP, Hôpital Necker, Paris France.
7
Pediatric Hematology Department, Cairo University Pediatric Hospital, Cairo, Egypt.
8
Faculty of Medicine, Ain Shams Center, University - Department Pediatrics, Cairo, Egypt.
9
Jehangir Clinical Development Centre, Department of Hematology, Jehangir Hospital Premises, Pune.
10
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical.
11
Bonn University, Germany.
12
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
13
University Milan, Italy.
14
INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris; sebastien.lacroix-desmazes@crc.jussieu.fr.

KEYWORDS:

FVIII; FVIII inhibitors; Hemophilia; Immunogenicity; VWF

PMID:
30705098
DOI:
10.3324/haematol.2018.212001
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center